<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H60EAACB01D7E4FDFBDF30916ACF2B914" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2113 IH: Speeding Access to Already Approved Pharmaceuticals Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-04-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2113</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170420">April 20, 2017</action-date><action-desc><sponsor name-id="S001187">Mr. Stivers</sponsor> (for himself and <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved
			 for marketing in the European Union.</official-title></form>
	<legis-body id="H2E1F5D7C09C747A4BB6F222406338BFA" style="OLC">
 <section id="HC564A13682EA434591004B2837A22BD3" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Speeding Access to Already Approved Pharmaceuticals Act of 2017</short-title></quote>.</text> </section><section id="H6892DC7DE20445B2A79FAB0AC8139F4E"><enum>2.</enum><header>Expedited review of EU-approved pharmaceuticals</header> <text display-inline="no-display-inline">Section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H75001F17CDA54A21B9C4591E55C916C3" style="OLC">
				<subsection id="H5029EFA83B7F4549A42DEDA6F7EB50F5"><enum>(i)</enum><header>EU-Approved pharmaceuticals</header>
 <paragraph id="HB14432ECB7144A39A316AC1AF803D552"><enum>(1)</enum><header>Expedited review</header><text>Beginning not later than 90 days after a new pharmaceutical is approved for marketing in the European Union, the Secretary shall, at the request of the sponsor of the pharmaceutical, facilitate the development and expedite the review of such new pharmaceutical under section 505 or 515 of this Act or section 351 of the Public Health Service Act, as appropriate.</text>
 </paragraph><paragraph id="H3AF83DBBCCFD424598730F86DC42F89E"><enum>(2)</enum><header>Definition</header><text>In this subsection, the term <term>pharmaceutical</term> means a drug (including a biological product) or a device.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </section></legis-body></bill> 

